TrialLancet (London, England)2022

Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial.

Eduardo Ramacciotti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.